Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inamed

This article was originally published in The Gray Sheet

Executive Summary

McGhan Medical subsidiary's round saline breast implants used for augmentation will cost 12% more as of Sept. 15, parent company Inamed says in an Aug. 7 release. The price hike is the first in five years and may affect third quarter financials depending on the reaction of customers and competitors, according to company President and CEO Ilan Reich. Recent speculation over breast implant price erosion has raised concern on Wall Street (1"The Gray Sheet" July 31, p. 7)

You may also be interested in...



Inamed Finalizing Lap-Band Treatment IDE Plans, Collecting Three-Year Data

Inamed is expecting to hear from FDA within the next few weeks about expanding its Lap-Band obesity treatment training program under a treatment investigational device exemption, President and co-CEO Ilan Reich told a July 25 teleconference announcing second-quarter financial results.

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.

UsernamePublicRestriction

Register

MT013730

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel